Atorvastatin: uses, dosing, side effects & brands
Atorvastatin is a hmg-coa reductase inhibitor sold in the U.S. under 2 brand and generic names, for coronary artery disease, hypercholesterolemia and hyperlipoproteinemias. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Hmg-Coa Reductase Inhibitor
- Treats (across its forms)
- Coronary Artery Disease, Hypercholesterolemia and Hyperlipoproteinemias
- Available as
- Suspension · Tablet
- Sold as
- 2 products — Atorvaliq and Lipitor
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
- Half-life
- about 14 hours
- What the pharmacy pays
- about $0.92 for a 30-count supply — not your price
How Atorvaliq is dosed
From the FDA label for Atorvaliq (application NDA213260). Other atorvastatin products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Take orally once daily, only on an empty stomach ( 2.1 ). • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ATORVALIQ, and adjust dosage if necessary ( 2.1 ). • Adults ( 2.2 ): o Recommended starting dosage is 10 or 20 mg once daily; dosage range is 10 mg to 80 mg once daily. o Patients requiring LDL-C reduction >45% may start at 40 mg once daily. • Pediatric Patients Aged 10 Years of Age and Older with HeFH: Recommended starting dosage is 10 mg once daily; dosage range is 10 to 20 mg once daily ( 2.3 ). • Pediatric Patients Aged 10 Years of Age and Older with HoFH: Recommended starting dosage is 10 to 20 mg once daily; dosage range is 10 to 80 mg once daily ( 2.4 ). • See full prescribing information for ATORVALIQ dosage modifications due to drug interactions ( 2.5 ). 2.1 Important Dosage and Administration Information • Measure the ATORVALIQ dose using a calibrated oral syringe or other oral dosing device scored using metric units of measurements (i.e., mL). • Take ATORVALIQ orally once daily at any time of day, only on an empty stomach (1 hour before or 2 hours after a meal). • Advise patients to take a missed dose as soon as possible. If the dose was missed by more than 12 hours, patients should not take the missed dose and resume with the next scheduled dose. • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating…
Everything below is the FDA label for Atorvaliq (suspension). Atorvastatin is also sold as tablet, and those are different medicines to take — follow the label for the one you were prescribed.
Atorvaliq side effects
The following important adverse reactions are described below and elsewhere in the labeling: • Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.1) ] • Immune-Mediated Necrotizing Myopathy [see Warnings and Precautions (5.2) ] • Hepatic Dysfunction [see Warnings and Precautions (5.3) ] • Increases in HbA1c and Fasting Serum Glucose Levels [see Warnings and Precautions (5.4) ] Most common adverse reactions (incidence ≥5%) are nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, Inc. at 1-844-321-1443, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ATORVALIQ has been established in adequate and well-controlled trials of atorvastatin calcium tablets, referenced below as “atorvastatin” [see Clinical Studies (14) ]. In the atorvastatin placebo-controlled clinical trial database of 16,066 patients (8,755 atorvastatin vs. 7,311 placebo; age range 10-93 years, 39% women, 91% White, 3% Black, 2% Asian, 4% other) with a median treatment duration of 53 weeks, the most…
Who shouldn’t take Atorvaliq
ATORVALIQ is contraindicated in patients with: • Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3) ] • Hypersensitivity to atorvastatin or any excipients in ATORVALIQ. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported [see Adverse Reactions (6.2) ] . • Acute liver failure or decompensated cirrhosis ( 4 ). • Hypersensitivity to atorvastatin or any excipient in ATORVALIQ ( 4 ).
Atorvaliq drug interactions
See full prescribing information for details regarding concomitant use of ATORVALIQ with other drugs or grapefruit juice that increase the risk of myopathy and rhabdomyolysis ( 2.5 , 7.1 ). • Rifampin: May reduce atorvastatin plasma concentrations. Administer simultaneously with ATORVALIQ ( 7.2 ). • Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.3 ). • Digoxin: May increase digoxin plasma levels; monitor patients appropriately ( 7.3 ). 7.1 Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with ATORVALIQ Atorvastatin is a substrate of CYP3A4 and transporters (e.g., OATP1B1/1B3, P-gp, or BCRP). Atorvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP3A4 and transporters. Table 2 includes a list of drugs that may increase exposure to atorvastatin and may increase the risk of myopathy and rhabdomyolysis when used concomitantly and instructions for preventing or managing them [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . Table 2: Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with ATORVALIQ Cyclosporine or Gemfibrozil Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of atorvastatin and cyclosporine, an inhibitor of CYP3A4 and OATP1B1 [see Clinical Pharmacology (12.3) ] . Gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine or gemfibrozil with ATORVALIQ. Intervention: Concomitant use of cyclosporine or gemfibrozil with ATORVALIQ is not recommended. Anti-Viral Medications Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of ATORVALIQ with many anti-viral medications, which are inhibitors of CYP3A4 and/or transporters (e.g., BCRP, OATP1B1/1B3, P-gp, MRP2, and/or OAT2) [see Clinical Pharmacology (12.3) ] . Cases of myopathy and rhabdomyolysis have been reported with concomitant use of ledipasvir plus sofosbuvir with atorvastatin. Intervention: • Concomitant use of tipranavir plus ritonavir or glecaprevir plus pibrentasvir with ATORVALIQ is not recommended. • In patients taking lopinavir plus ritonavir, or simeprevir, consider the risk/benefit of concomitant use with ATORVALIQ. • In patients taking saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir or letermovir, do not exceed ATORVALIQ 20 mg. • In patients taking nelfinavir, do not exceed ATORVALIQ 40 mg [see Dosage and Administration (2.5) ]. • Consider the risk/benefit of concomitant use of ledipasvir plus sofosbuvir with ATORVALIQ. • Monitor all patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Examples: Tipranavir plus ritonavir, glecaprevir plus pibrentasvir, lopinavir plus ritonavir, simeprevir, saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir, letermovir, nelfinavir, and ledipasvir plus sofosbuvir. Select Azole Antifungals or Macrolide Antibiotics Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of ATORVALIQ with select azole antifungals or macrolide antibiotics, due to inhibition of CYP3A4 and/or transporters [see Clinical Pharmacology (12.3) ] . Intervention: In patients taking clarithromycin or itraconazole, do not exceed ATORVALIQ 20 mg [see Dosage and Administration (2.5) ] . Consider the risk/benefit of concomitant use of other azole antifungals or macrolide antibiotics with ATORVALIQ. Monitor all patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Examples: Erythromycin, clarithromycin, itraconazole, ketoconazole, posaconazole, and voriconazole. Niacin Clinical Impact: Cases of myopathy and rhabdomyolysis have been observed with concomitant use of lipid modifying dosages of niacin (≥1 gram/day niacin) with atorvastatin [see Warnings and Precaustions (5.1) ] . Intervention: Consider if the benefit of using lipid modifying dosages of niacin concomitantly with ATORVALIQ outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Fibrates (other than Gemfibrozil) Clinical Impact: Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with ATORVALIQ. Intervention: Consider if the benefit of using fibrates concomitantly with ATORVALIQ outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Colchicine Clinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with atorvastatin. Intervention: Consider the risk/benefit of concomitant use of colchicine with ATORVALIQ. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Grapefruit Juice Clinical Impact: Grapefruit juice consumption, especially excessive consumption, more than 1.2 liters/daily, can raise the plasma levels of atorvastatin and may increase the risk of myopathy and rhabdomyolysis. Intervention: Avoid intake of large quantities of grapefruit juice, more than 1.2 liters daily, when taking ATORVALIQ. 7.2 Drug Interactions that may Decrease Exposure to ATORVALIQ Table 3 presents drug interactions that may decrease exposure to ATORVALIQ and instructions for preventing or managing them. Table 3: Drug Interactions that may Decrease Exposure to ATORVALIQ Rifampin Clinical Impact: Concomitant administration of atorvastatin with rifampin, an inducer of cytochrome P450 3A4 and inhibitor of OATP1B1, can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, delayed administration of ATORVALIQ after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. Intervention: Administer ATORVALIQ and rifampin simultaneously. 7.3 ATORVALIQ Effects on Other Drugs Table 4 presents atorvastatin’s effect on other drugs and instructions for preventing or managing them. Table 4: ATORVALIQ Effects on Other Drugs Oral Contraceptives Clinical Impact: Co-administration of atorvastatin and an oral contraceptive increased plasma concentrations of norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3) ]. Intervention: Consider this when selecting an oral contraceptive for patients taking ATORVALIQ. Digoxin Clinical Impact: When multiple doses of atorvastatin and digoxin were co-administered, steady state plasma digoxin concentrations increased [see Clinical Pharmacology (12.3) ]. Intervention: Monitor patients taking digoxin appropriately. Drug Interactions Atorvastatin is a substrate of the hepatic transporters, OATP1B1 and OATP1B3 transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the efflux transporter BCRP, which may limit the intestinal absorption and biliary clearance of atorvastatin. Table 5: Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin Co-administered drug and dosing regimen Atorvastatin Dose (mg) Ratio of AUC Represents ratio of treatments (co-administered drug plus atorvastatin vs. atorvastatin alone). Ratio of Cmax See Sections 5.1 and 7 for clinical significance. Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD Once daily for 28 days 8.69 10.66 Tipranavir 500 mg BID Twice daily /ritonavir 200 mg BID , 7 days 10 mg SD Single dose 9.36 8.58 Glecaprevir 400 mg QD /pibrentasvir 120 mg QD , 7 days 10 mg QD for 7 days 8.28 22.00 Telaprevir 750 mg q8h Every 8 hours , 10 days 20 mg SD 7.88 10.60 , The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used. Saquinavir 400 mg BID /ritonavir 400 mg BID , 15 days 40 mg QD for 4 days 3.93 4.31 Elbasvir 50 mg QD /grazoprevir 200 mg QD , 13 days 10 mg SD 1.94 4.34 Simeprevir 150 mg QD , 10 days 40 mg SD 2.12 1.70 Clarithromycin 500 mg BID , 9 days 80 mg QD for 8 days 4.54 5.38 Darunavir 300 mg BID /ritonavir 100 mg BID , 9 days 10 mg QD for 4 days 3.45 2.25 Itraconazole 200 mg QD , 4 days 40 mg SD 3.32 1.20 Letermovir 480 mg QD , 10 days 20 mg SD 3.29 2.17 Fosamprenavir 700 mg BID /ritonavir 100 mg BID , 14 days 10 mg QD for 4 days 2.53 2.84 Fosamprenavir 1400 mg BID , 14 days 10 mg QD for 4 days 2.3 4.04 Nelfinavir 1250 mg BID , 14 days 10 mg QD for 28 days 1.74 2.22 Grapefruit Juice, 240 mL QD , Greater increases in AUC (ratio of AUC up to 2.5) and/or Cmax (ratio of Cmax up to 1.71) have been reported with excessive grapefruit consumption (≥ 750 mL-1.2 liters per day). 40 mg SD 1.37 1.16 Diltiazem 240 mg QD , 28 days 40 mg SD 1.51 1.00 Erythromycin 500 mg QID Four times daily , 7 days 10 mg SD 1.33 1.38 Amlodipine 10 mg, single dose 80 mg SD 1.18 0.91 Cimetidine 300 mg QID , 2 weeks 10 mg QD for 2 weeks 1.00 0.89 Colestipol 10 g BID , 24 weeks 40 mg QD for 8 weeks NA 0.74 Ratio based on a single sample taken 8-16 h post dose. Maalox TC ® 30 mL QID , 17 days 10 mg QD for 15 days 0.66 0.67 Efavirenz 600 mg QD , 14 days 10 mg for 3 days 0.59 1.01 Rifampin 600 mg QD , 7 days (co‑administered) Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. 40 mg SD 1.12 2.90 Rifampin 600 mg QD , 5 days (doses separated) 40 mg SD 0.20 0.60 Gemfibrozil 600 mg BID , 7 days 40 mg SD 1.35 1.00 Fenofibrate 160 mg QD , 7 days 40 mg SD 1.03 1.02 Boceprevir 800 mg TID Three times daily , 7 days 40 mg SD 2.32 2.66 Table 6: Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs Atorvastatin Co-administered drug and dosing regimen Drug/Dose (mg) Ratio of AUC Ratio of Cmax 80 mg QD Once daily for 15 days Antipyrine, 600 mg SD Single dose 1.03 0.89 80 mg QD for 10 days See Section 7 for clinical significance. Digoxin 0.25 mg QD , 20 days 1.15 1.20 40 mg QD for 22 days Oral contraceptive QD , 2 months - norethindrone 1 mg - ethinyl estradiol 35 µg 1.28 1.19 1.23 1.30 10 mg SD Tipranavir 500 mg BID Twice daily /ritonavir 200 mg BID , 7 days 1.08 0.96 10 mg QD for 4 days Fosamprenavir 1400 mg BID , 14 days 0.73 0.82 10 mg QD for 4 days Fosamprenavir 700 mg BID /ritonavir 100 mg BID , 14 days 0.99 0.94 Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.
Atorvastatin and food
Grapefruit & grapefruit juice
Avoid grapefruit and grapefruit juice with this medicine unless your pharmacist or the label says it's fine — check, because not every drug in a class is affected the same way.
Grapefruit Juice and Some Drugs Don't Mix — U.S. FDA ↗
Every atorvastatin product we track (2)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | Not yet rated | Prescription | Suspension | Generic | $1 | View → | |
| 2 | Not yet rated | Prescription | Tablet | Generic | $1 | View → |
What atorvastatin pills look like
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| TV;AT1 | 10 mg | white | oval | — |
| TV;AT20 | 20 mg | white | oval | — |
| TV;AT40 | 40 mg | white | oval | — |
| TV;AT80 | 80 mg | white | oval | — |
| TV;5056 | 10 mg | white | oval | — |
| TV;5059 | 20 mg | white | oval | — |
| TV;5058 | 40 mg | white | oval | — |
| TV;5057 | 80 mg | white | oval | — |
| APO;ATV20 | 20 mg | white | oval | — |
| APO;A10 | 10 mg | white | oval | — |
| APO;ATV20 | 20 mg | white | oval | — |
| APO;ATV40 | 40 mg | white | oval | — |
Combination products containing atorvastatin
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
Atorvastatin recalls
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Atorvastatin Calcium Tablets USP
Failed Dissolution Specifications
Ascend Laboratories, LLC · Sep 19, 2025
Atorvastatin Calcium Tablets USP
Failed Dissolution Specifications
Ascend Laboratories, LLC · Sep 19, 2025
Atorvastatin Calcium Tablets USP
Failed Dissolution Specifications
Ascend Laboratories, LLC · Sep 19, 2025
Atorvastatin Calcium Tablets USP
Failed Dissolution Specifications
Ascend Laboratories, LLC · Sep 19, 2025
Atorvastatin Calcium Tablets USP 40 mg
Failed dissolution specifications: lower than specifications
BIOCON PHARMA INC · Mar 17, 2025
Atorvastatin and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for atorvastatin: levels in milk, effects in breastfed infants, and the drugs it would consider insteadThe consensus opinion is that women taking a statin should not breastfeed because of a concern with disruption of infant lipid metabolism. However, others have argued that children homozygous for familial hypercholesterolemia are treated with statins beginning at 1 year of age, that statins have low oral bioavailability, and risks to the breastfed infant are low, especially with rosuvastatin and pravastatin. Some evidence indicates that amounts of atorvastatin and its metabolites are milk are very low and it can be taken by nursing mothers with no obvious developmental problems in their infants. Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
National Institute of Child Health and Human Development, record revised July 15, 2026. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about atorvastatin
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 75,234 reports naming atorvastatin, and the FDA flagged 64% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- fatigue4,892 reports
- diarrhoea4,390 reports
- nausea4,071 reports
- dyspnoea4,014 reports
- headache3,621 reports
- dizziness3,250 reports
- myalgia2,739 reports
- asthenia2,737 reports
Read these as a signal, not a rate. A report does not mean atorvastatin caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved August 25, 2026.
How long atorvastatin stays in your system
The elimination half-life of atorvastatin is about 14 hours. This is the parent drug's plasma elimination half-life; because atorvastatin has active metabolites, its cholesterol-lowering (HMG-CoA reductase-inhibiting) activity lasts materially longer, about 20 to 30 hours.
LIPITOR (atorvastatin calcium) tablet, film coated — DailyMed FDA label, Section 12.3 Pharmacokinetics ↗Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.
Related guides
Related calculators
Frequently asked questions
What is Atorvaliq?
Atorvaliq (Atorvastatin Calcium) is a HMG-CoA reductase inhibitor used to treat Coronary Artery Disease, Hypercholesterolemia, Hyperlipoproteinemias, Hypertriglyceridemia.
What kind of drug is atorvastatin?
The FDA classifies atorvastatin as a hmg-coa reductase inhibitor. Statins block HMG-CoA reductase, the key enzyme the liver uses to make cholesterol. With less cholesterol being produced, the liver pulls more LDL ("bad") cholesterol out of the blood, lowering overall blood cholesterol levels. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
How long does atorvastatin stay in your system?
The elimination half-life of atorvastatin is about 14 hours — that is how long the body takes to clear half of a dose. This is the parent drug's plasma elimination half-life; because atorvastatin has active metabolites, its cholesterol-lowering (HMG-CoA reductase-inhibiting) activity lasts materially longer, about 20 to 30 hours. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.
Can you take atorvastatin with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run atorvastatin against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is atorvastatin sold under?
We track 2 atorvastatin-containing products in the U.S.: Atorvaliq and Lipitor. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does atorvastatin come in?
Across the brands we track, atorvastatin is currently marketed as suspension and tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic atorvastatin?
We do not currently list a generic-labelled atorvastatin product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Has atorvastatin been recalled?
The FDA's Enforcement database lists at least 5 recall records whose product description mentions atorvastatin. The most recent: Atorvastatin Calcium Tablets USP (Sep 19, 2025). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.
How long does it take for atorvastatin to work?
Atorvastatin is not something you feel working. It starts lowering LDL cholesterol within about 2 weeks, with most of the effect reached by around 4 weeks of daily use. The only way to know it is working is a blood test (lipid panel), which your prescriber usually rechecks about 4 to 6 weeks after starting or changing the dose. Keep taking it daily even though nothing feels different.
What should I avoid while taking atorvastatin?
Food: grapefruit and grapefruit juice (and, for some drugs, seville oranges) — see the food section above for what each one does and whether it means avoiding it or just being consistent. This is what the FDA label and our cited sources say — it is not a complete list. Your pharmacist can check your own combination.
What are the common side effects of atorvastatin?
Most people tolerate atorvastatin well, and the everyday side effects are usually mild. In placebo-controlled trials the FDA label lists the most common reactions (2% or more of patients) as cold-like nasal symptoms (nasopharyngitis), joint pain (arthralgia), diarrhea, pain in an arm or leg, and urinary tract infection. MedlinePlus adds diarrhea, heartburn, gas, joint pain, and occasional forgetfulness, memory loss, or confusion. Muscle aches are the symptom atorvastatin is most known for — Mayo Clinic describes it as soreness, tiredness, or weakness in the muscles, usually mild. Tell your prescriber if any of these are severe or do not go away, but do not stop the medicine on your own.
What are the serious side effects of atorvastatin — when should I call a doctor?
Per MedlinePlus, call your doctor right away or get emergency help if you have any of these. Muscle problems: "muscle pain, tenderness, or weakness; lack of energy, extreme tiredness or weakness; fever; flu-like symptoms" — severe or unexplained muscle pain, especially with dark-colored urine, can signal rhabdomyolysis, a rare but dangerous breakdown of muscle. Liver problems: "nausea; unusual bleeding or bruising; loss of appetite; pain in the upper right part of the stomach; dark-colored urine; yellowing of the skin or eyes." Severe allergic reaction: "rash, itching, hives, difficulty breathing or swallowing; swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs; hoarseness." Also seek help for chest pain, or (per NHS) severe stomach pain that could indicate pancreatitis. This is not a complete list — report anything that worries you.
How worried should I be about atorvastatin and muscle pain?
Less than the reputation suggests. Mayo Clinic reports that the real risk of muscle pain from a statin is about 5% or less compared with a placebo (a dummy pill), and studies found people quit over muscle aches even when they were unknowingly taking the placebo — a "nocebo effect," where expecting a side effect makes you more likely to report it. So a lot of muscle pain blamed on atorvastatin is not actually caused by it. The rare, serious version — rhabdomyolysis — is what to watch for: Mayo notes only a few cases occur per million people taking statins, and the FDA label says risk rises with age over 65, untreated hypothyroidism, kidney impairment, high doses, or combining atorvastatin with certain drugs (fibrates, cyclosporine, or strong CYP3A4 inhibitors like clarithromycin). The red flag is severe or unexplained muscle pain plus dark urine — call your doctor then.
What are the long-term side effects of atorvastatin?
Atorvastatin is usually taken for years, and two documented longer-term risks are worth knowing. First, blood sugar: Mayo Clinic notes statins can raise blood sugar and are linked to a small increased risk of developing type 2 diabetes — the cardiovascular benefit generally still outweighs this for people who need the drug, and it does not mean stopping. Second, liver enzymes: the FDA label warns that persistent elevations in liver enzymes (transaminases) can occur, which is why prescribers check liver enzymes before and sometimes during treatment; a mild rise often does not require stopping, per Mayo. Memory or confusion reported by some users is generally not permanent. These are managed by your prescriber through monitoring and dose adjustment, not by quitting on your own.
When do atorvastatin side effects start and how long do they last?
Honestly, the timeline varies and the sources do not give a fixed day count. Mild digestive or muscle symptoms, if they occur, tend to show up in the first weeks of starting or after a dose increase, and many settle as your body adjusts. Because muscle aches are so often a nocebo effect rather than the drug (Mayo), some symptoms fade or turn out to be unrelated. Liver enzyme changes and blood sugar effects develop over longer use, which is why they are caught by periodic blood tests rather than by how you feel. Serious reactions — an allergic reaction, or muscle pain with dark urine — can happen at any point and need prompt attention. If a side effect is persistent or bothersome, your prescriber can try a lower dose or a different statin rather than having you stop.
Can I stop taking atorvastatin if it causes side effects?
Not on your own — this is a decision for your prescriber. Mayo Clinic is explicit: "If you think your statins are causing side effects, don't just stop taking the pills. Talk to your healthcare team." Stopping abruptly removes the heart-attack and stroke protection the drug provides. Often there is a fix short of quitting — a lower dose, a switch to a different statin, or checking whether another medication or condition is really behind your symptoms. The exception is an emergency: if you have signs of a severe allergic reaction, or severe muscle pain with dark urine, get medical help immediately and let the clinician guide next steps.
Cite this page
- APA
- pharmaranks. (2026, July 24). Atorvastatin: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/atorvastatin
- MLA
- “Atorvastatin: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/atorvastatin.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for atorvastatin on DailyMed (NIH) ↗.